Axalta Coating Systems vs Chemours
AXTA and CC side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXTA and CC compare
Axalta Coating Systems is the larger company, worth 3.8 times as much as Chemours ($7.9B against $2.1B).
Axalta Coating Systems grew revenue faster over the last twelve months (0.14% versus 0.07% for Chemours).
Axalta Coating Systems keeps more of each dollar of sales as profit, with a net margin of 6.5% compared with −2.6% at Chemours.
Chemours pays a dividend yielding 2.6%; Axalta Coating Systems does not pay one.
Axalta Coating Systems scores higher on the StockData Score (12 against 5 for Chemours), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXTA | CC |
|---|---|---|
| Size and price | ||
| Market cap | $7.9B | $2.1B |
| Share price | $37.07 | $13.72 |
| Change, 1 year | 28.9% | 7.6% |
| Change, 5 years | 11.3% | −56.8% |
| Beta (5Y) | 1.09 | 1.57 |
| Employees | 12K | 5,700 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 4 (better) | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 4 (better) | 1 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 23.9× | – |
| P/S | 1.5× | 0.4× (better) |
| P/B | 3.0× (better) | 13.3× |
| EV/EBITDA | 10.9× | 7.2× (better) |
| P/FCF | 16.0× | 9.8× (better) |
| PEG | 0.90 | – |
| FCF yield | 6.3% | 10.2% (better) |
| Fair value | $40.51 | – |
| Margin of safety | 8.5% | – |
| Growth | ||
| Revenue growth (TTM) | 0.14% (better) | 0.07% |
| Revenue growth, 5Y average | 6.5% (better) | 3.2% |
| Net income growth (TTM) | −26.6% | – |
| EPS growth (TTM) | −25.8% | – |
| EPS growth, 5Y average | 27.3% | – |
| Profitability | ||
| Gross margin | 33.6% (better) | 15.2% |
| Operating margin | 12.4% | – |
| Net margin | 6.5% (better) | −2.6% |
| FCF margin | 9.6% (better) | 3.6% |
| Return on equity | 13.6% (better) | −71.8% |
| Return on invested capital | 8.8% | – |
| Financial health | ||
| Debt / equity | 1.14 (better) | 24.73 |
| Net debt / EBITDA | 2.47 (better) | 4.32 |
| Interest coverage | 4.2× | – |
| Current ratio | 1.53 | 1.81 (better) |
| Altman Z-score | 2.46 (better) | 1.42 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 2.6% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | −12.5% |
| Shareholder yield | 0.00% | 2.6% (better) |
| Ownership | ||
| Held by institutions | 106% | 90.2% |
| Held by insiders | 0.49% | 0.96% |
| Insider net buying, 12 months | – | $489K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.2% | 9.8% |
Go deeper
- AXTA stock overview
- AXTA income statement
- AXTA valuation and score
- CC stock overview
- CC income statement
- CC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.